-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Lacutamab in Transformed Mycosis Fungoides
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Lacutamab in Transformed Mycosis Fungoides Drug Details: Lacutamab (IPH-4102) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Lacutamab in Natural Killer Cell Lymphomas
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Lacutamab in Natural Killer Cell Lymphomas Drug Details: Lacutamab (IPH-4102) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Lacutamab in Peripheral T-Cell Lymphomas (PTCL)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Lacutamab in Peripheral T-Cell Lymphomas (PTCL) Drug Details: Lacutamab (IPH-4102) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Lacutamab in Follicular Lymphoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Lacutamab in Follicular Lymphoma Drug Details: Lacutamab (IPH-4102) is under development for the treatment...
-
Product Insights
![]()
Net Present Value Model: Lacutamab
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Lacutamab Drug Details Lacutamab (IPH-4102) is...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – lacutamab
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry lacutamab Drug Details Lacutamab (IPH-4102) is under development for the treatment of relapsed and...
-
Track & Monitor
![]()
Smart Money Investing in the Financial Services Industry – Q4 2017: Tracking M&A, venture capital, and private equity investments globally
"Smart Money Investing in the Financial Services Industry - Q4 2017", report provides detailed analysis of investment activities in financial services industry globally during the fourth quarter of 2017. The report provides comprehensive coverage of investment activities including mergers, acquisitions, asset transactions, venture financing and private equity, both in terms of deal value and volume. It also provides a global snapshot of investment trends in sectors including banking, payments, insurance and wealth management, and information on best practices followed by...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.